Kyverna Therapeutics (KYTX) Other financing activities (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Other financing activities data on file, last reported at $243000.0 in Q1 2026.

• Quarterly Other financing activities rose 8000.0% year-over-year to $243000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (up 74133.33% YoY) and the FY2025 annual result came in at $2.0 million, down 99.42% from the prior year.
• Other financing activities eased to $243000.0 in Q1 2026, from $2.0 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $341.2 million in Q1 2024 to a low of -$341.0 million in Q2 2024.
• A 4-year average of $28.7 million and a median of $166500.0 in 2024 frame the typical range for Other financing activities.
• The widest YoY moves for Other financing activities: up 1421445.83% in 2024, down 947416.67% in 2024.
• Tracing KYTX's Other financing activities over 4 years: stood at $275000.0 in 2023, then soared by 123879.64% to $340.9 million in 2024, then sank by 99.42% to $2.0 million in 2025, then sank by 87.77% to $243000.0 in 2026.
• The last three Other financing activities figures came in at $243000.0 (Q1 2026), $2.0 million (Q4 2025), and -$3000.0 (Q2 2025), per Business Quant data.